15-min delayed · Jul 28, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 10 firms covering Arcus Biosciences Inc, 7 rate it Buy or better, 3 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. Targets range widely, $22.00 to $49.00 (about 2.2x), a sign of real disagreement on valuation. The average target of $36.60 sits 35% above the current $27.06. The rating mix has stayed broadly stable, with Buy-side ratings edging up from 6 to 7 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.83 next quarter toward $-3.10 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS10 ratings
Moderate Buy
Strong Buy00%
Buy770%
Hold330%
Sell00%
Strong Sell00%
Based on 10 analysts giving stock ratings to Arcus Biosciences Inc.
As of Jul, 7 of 10 firms rate RCUS a Buy (3 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
RCUS EPS & revenue forecast
EPS · NEXT QUARTER
$-0.83
Range $-1.07 – $-0.55 · 7 analysts · -35% YoY
Next period, 7 analysts expect Arcus Biosciences Inc to earn $-0.83 a share (range $-1.07 – $-0.55), versus $-1.27 a year earlier. Full-year consensus is $-3.48, growing to $-3.10 the year after.
REVENUE · NEXT QUARTER
$19.5M
Range $0 – $45.0M · 7 analysts · -25% YoY
Revenue is expected to reach $19.5M (range $0 – $45.0M), -25.1% year-over-year. Full-year consensus is $85.1M, rising to $93.1M next year.
Top analysts covering Arcus Biosciences Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on RCUS.
#1
Yigal Nochomovitz
Citigroup · Rank #131
Buy
$45.00+66.3% to target
Overall win rate
43%
+ Follow
#2
Li Watsek
Cantor Fitzgerald · Rank #218
Buy
No targeton RCUS
Overall win rate
38%
+ Follow
#3
Robert Driscoll
Wedbush · Rank #313
Buy
$41.00+51.5% to target
Overall win rate
30%
+ Follow
#4
Emily Bodnar
HC Wainwright & Co. · Rank #338
Buy
$45.00+66.3% to target
Overall win rate
22%
+ Follow
#5
Terence Flynn
Morgan Stanley
Hold
$22.00-18.7% to target
Coverage
—
+ Follow
RCUS stock forecast FAQ
What is RCUS's average 12-month price target?+
The 10 analysts with a live target average $36.60 for Arcus Biosciences Inc over the next 12 months, ranging from a $49.00 high to a $22.00 low.
Is RCUS stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 10 analyst ratings, 7 are Buy or Strong Buy, 3 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for RCUS?+
The Street-high target is $49.00 (Leerink Partners), and the Street-low is $22.00 (Morgan Stanley). The average of all 10 active targets is $36.60.
How many Wall Street analysts cover RCUS?+
10 analysts have an active rating on Arcus Biosciences Inc, and 10 firms carry a live 12-month price target.
Who is the most accurate analyst covering RCUS?+
Among analysts who currently cover RCUS, Yigal Nochomovitz of Citigroup has the strongest overall Quantellect track record (Rank #131). Their current call is Buy with a $45.00 target.
What is Arcus Biosciences Inc's projected EPS for next quarter?+
The consensus estimate is $-0.83 per share (range $-1.07 – $-0.55) across 7 analysts. Full-year EPS is projected at $-3.48, rising to $-3.10 the following year.
How much revenue is Arcus Biosciences Inc expected to report next quarter?+
Consensus revenue is $19.5M (range $0 – $45.0M). Full-year revenue is projected at $85.1M, growing to $93.1M next year.
Have analysts been upgrading or downgrading RCUS lately?+
As of Jul, 7 of 10 firms rate RCUS a Buy (3 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their RCUS calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
